- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Announces Global License and Development Rights Agreement with Hanmi Pharmaceutical for Novel Clinical Stage Biologic to Treat Diabetes and Obesity
Novel Oxyntomodulin-Based Therapy Bolsters Janssen’s Metabolism Portfolio
First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Announced
Injectable combinations once every 4 or 8 weeks show comparable efficacy versus daily oral combination therapy
U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of Patients with Unresectable or Metastatic Liposarcoma or Leiomyosarcoma, Two Common Subtypes of Soft Tissue Sarcoma
Approval based on largest Phase 3 study conducted to date in this patient population
Phase 3 Data Show STELARA® Induced Clinical Response And Remission In The Treatment Of Patients With Moderate To Severe Crohn’s Disease
Efficacy and Safety Results from First STELARA® Phase 3 Induction Study (UNITI-2)
IMBRUVICA® (ibrutinib) Supplemental New Drug Application for Treatment-naïve Chronic Lymphocytic Leukemia Submitted to the U.S. FDA
Submission seeking potential fifth indication based on data from the Phase 3 RESONATE™-2 (PCYC-1115) trial
Johnson & Johnson Announces BARDA Funding Award to Accelerate Ebola Vaccine Program
Prime-boost vaccine regimen in development at the Janssen Pharmaceutical Companies currently in Phase I and II clinical studies in Europe, U.S. and Africa
U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma
If approved, daratumumab will offer a new option for double refractory, heavily pre-treated patients
Data Published in The New England Journal of Medicine Show Single-Agent Daratumumab Demonstrated a 36 Percent Overall Response Rate and Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients
Study results also showed 65 percent of responding patients remained in remission at 12 months